Brainstorm Cell Therapeutics INC 8-K filings

Brainstorm Cell Therapeutics has announced a $4 million registered direct offering of common stock and warrants to a single institutional investor.

BrainStorm Cell Therapeutics has reached an agreement with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b clinical trial for NurOwn, an investigational therapy for ALS.

Brainstorm Cell Therapeutics has appointed Dr. Hartoun Hartounian as its new Executive Vice President and Chief Operating Officer, effective June 24, 2024, to enhance operational efficiency and support the commercial readiness of its therapeutic platforms.

Brainstorm Cell Therapeutics has received an extension from Nasdaq until October 21, 2024, to regain compliance with the minimum bid price requirement, potentially through a reverse stock split.

Brainstorm Cell Therapeutics is appealing a Nasdaq decision to delist its stock after failing to meet the minimum bid price requirement.

Brainstorm Cell Therapeutics announced the promotion of Dr. Bob Dagher to Chief Medical Officer and the transition of Dr. Stacy Lindborg from Co-CEO to a board member as the company prepares for a Phase 3b trial of NurOwn.

Brainstorm Cell Therapeutics has successfully regained compliance with Nasdaq's minimum market value requirement after a period of non-compliance.

BrainStorm Cell Therapeutics has received FDA agreement under a Special Protocol Assessment (SPA) for its Phase 3b trial of NurOwn in amyotrophic lateral sclerosis (ALS).

Brainstorm Cell Therapeutics has amended its distribution agreement, removing Leerink Partners as an agent for its at-the-market equity offering program.

BrainStorm Cell Therapeutics reported its full year 2023 financial results and provided an update on its NurOwn program, including plans for a confirmatory Phase 3b trial.